These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 34611964)

  • 1. Clinical significance of circulating tumour cells and tumour marker detection in the chemotherapeutic evaluation of advanced colorectal cancer.
    Shen F; Zhu Y; Wang F; Cai X; Ding H; Zhou F; Wang J; Gu H; Liu C; Li Q
    Colorectal Dis; 2022 Jan; 24(1):68-76. PubMed ID: 34611964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of epithelial-mesenchymal transition typing of circulating tumour cells in colorectal cancer.
    Hou J; Guo C; Lyu G
    Colorectal Dis; 2020 May; 22(5):581-587. PubMed ID: 31868956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating tumor cells as an independent prognostic factor in advanced colorectal cancer: a retrospective study in 121 patients.
    Wang L; Zhou S; Zhang W; Wang J; Wang M; Hu X; Liu F; Zhang Y; Jiang B; Yuan H
    Int J Colorectal Dis; 2019 Apr; 34(4):589-597. PubMed ID: 30627849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer.
    Barbazán J; Muinelo-Romay L; Vieito M; Candamio S; Díaz-López A; Cano A; Gómez-Tato A; Casares de Cal Mde L; Abal M; López-López R
    Int J Cancer; 2014 Dec; 135(11):2633-43. PubMed ID: 24752533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesenchymal marker and LGR5 expression levels in circulating tumor cells correlate with colorectal cancer prognosis.
    Wang W; Wan L; Wu S; Yang J; Zhou Y; Liu F; Wu Z; Cheng Y
    Cell Oncol (Dordr); 2018 Oct; 41(5):495-504. PubMed ID: 29949050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
    Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
    Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical relevance of EMT and stem-like gene expression in circulating tumor cells of metastatic colorectal cancer patients.
    Ning Y; Zhang W; Hanna DL; Yang D; Okazaki S; Berger MD; Miyamoto Y; Suenaga M; Schirripa M; El-Khoueiry A; Lenz HJ
    Pharmacogenomics J; 2018 Jan; 18(1):29-34. PubMed ID: 27503579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Prognostic Model Based on Circulating Tumour Cells is Useful for Identifying the Poorest Survival Outcome in Patients with Metastatic Colorectal Cancer.
    Chou WC; Wu MH; Chang PH; Hsu HC; Chang GJ; Huang WK; Wu CE; Hsieh JC
    Int J Biol Sci; 2018; 14(2):137-146. PubMed ID: 29483832
    [No Abstract]   [Full Text] [Related]  

  • 9. Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach.
    Ning Y; Hanna DL; Zhang W; Mendez A; Yang D; El-Khoueiry R; Matsusaka S; Sunakawa Y; Stremitzer S; Parekh A; Okazaki S; Berger MD; Barzi A; Lenz HJ
    Mol Cancer Ther; 2015 Oct; 14(10):2401-8. PubMed ID: 26227487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and Therapeutic Significance of Circulating Tumor Cell Phenotype Detection Based on Epithelial-Mesenchymal Transition Markers in Early and Midstage Colorectal Cancer First-Line Chemotherapy.
    Lu G; Lu Z; Li C; Huang X; Luo Q
    Comput Math Methods Med; 2021; 2021():2294562. PubMed ID: 34777560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinico-pathological correlation of serial measurement of circulating tumor cells in 24 metastatic colorectal cancer patients receiving chemotherapy reveals interpatient heterogeneity correlated with CEA levels but independent of KRAS and BRAF mutation.
    Das A; Kunkel M; Joudeh J; Dicker DT; Scicchitano A; Allen JE; Sarwani N; Yang Z; Kaifi J; Zhu J; Liao J; El-Deiry WS
    Cancer Biol Ther; 2015; 16(5):709-13. PubMed ID: 25806877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highly Correlated Recurrence Prognosis in Patients with Metastatic Colorectal Cancer by Synergistic Consideration of Circulating Tumor Cells/Microemboli and Tumor Markers CEA/CA19-9.
    Chu HY; Yang CY; Yeh PH; Hsu CJ; Chang LW; Chan WJ; Lin CP; Lyu YY; Wu WC; Lee CW; Wu JK; Jiang JK; Tseng FG
    Cells; 2021 May; 10(5):. PubMed ID: 34068719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of cell surface vimentin positive circulating tumor cells as a prognostic biomarker for stage III/IV colorectal cancer.
    Yu J; Yang M; Peng T; Liu Y; Cao Y
    Sci Rep; 2023 Nov; 13(1):18791. PubMed ID: 37914786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer.
    Lindsay CR; Le Moulec S; Billiot F; Loriot Y; Ngo-Camus M; Vielh P; Fizazi K; Massard C; Farace F
    BMC Cancer; 2016 Feb; 16():168. PubMed ID: 26923772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and clinicopathological significance of circulating tumor cells detected by RT-PCR in non-metastatic colorectal cancer: a meta-analysis and systematic review.
    Yang C; Zou K; Zheng L; Xiong B
    BMC Cancer; 2017 Nov; 17(1):725. PubMed ID: 29115932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic and predictive value of circulating tumor cell analysis in colorectal cancer patients.
    de Albuquerque A; Kubisch I; Stölzel U; Ernst D; Boese-Landgraf J; Breier G; Stamminger G; Fersis N; Kaul S
    J Transl Med; 2012 Nov; 10():222. PubMed ID: 23146106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Value of serum human epithelial growth factor receptor 2 extracellular domain and circulating tumor cells in evaluating therapeutic response in advanced gastric cancer].
    Li Y; Peng Z; Zhang X; Gong J; Shen L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Nov; 20(11):1293-1299. PubMed ID: 29178102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab.
    Sastre J; Vidaurreta M; Gómez A; Rivera F; Massutí B; López MR; Abad A; Gallen M; Benavides M; Aranda E; Rubio ED;
    Clin Colorectal Cancer; 2013 Dec; 12(4):280-6. PubMed ID: 24012456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab.
    Musella V; Pietrantonio F; Di Buduo E; Iacovelli R; Martinetti A; Sottotetti E; Bossi I; Maggi C; Di Bartolomeo M; de Braud F; Daidone MG; Cappelletti V
    Int J Cancer; 2015 Sep; 137(6):1467-74. PubMed ID: 25704501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of pancreatic circulating tumor cells using combined negative enrichment and immunostaining-fluorescence in situ hybridization.
    Gao Y; Zhu Y; Zhang Z; Zhang C; Huang X; Yuan Z
    J Exp Clin Cancer Res; 2016 Apr; 35():66. PubMed ID: 27066900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.